The mortality-incidence ratio as an indicator of five-year cancer survival in metropolitan Lima

2.50
Hdl Handle:
http://hdl.handle.net/10757/622636
Title:
The mortality-incidence ratio as an indicator of five-year cancer survival in metropolitan Lima
Authors:
Stenning-Persivale, Karoline; Savitzky Franco, Maria Jose; Cordero-Morales, Alejandra; Cruzado-Burga, José; Poquioma, Ebert; Díaz Nava, Edgar; Payet, Edouardo
Citation:
The mortality-incidence ratio as an indicator of five-year cancer survival in metropolitan Lima 2018, 12 ecancermedicalscience
Publisher:
Cancer Intelligence
Journal:
ecancermedicalscience
Issue Date:
18-Jan-2018
URI:
http://hdl.handle.net/10757/622636
DOI:
10.3332/ecancer.2018.799
Additional Links:
http://www.ecancer.org/journal/12/full/799-the-mortality-incidence-ratio-as-an-indicator-of-five-year-cancer-survival-in-metropolitan-lima.php
Abstract:
Introduction: The Mortality–Incidence Ratio complement [1 – MIR] is an indicator validated in various populations to estimate five-year cancer survival, but its validity remains unreported in Peru. This study aims to determine if the MIR correlates directly with five-year survival in patients diagnosed with the ten most common types of cancer in metropolitan Lima. Materials and methods: The Metropolitan Lima Cancer Registry (RCLM in Spanish) for 2004–2005 was used to determine the number of new cases and the number of deaths of the following cancers: breast, stomach, prostate, thyroid, lung, colon, cervical, and liver cancers, as well as non-Hodgkin’s lymphoma and leukaemia. To determine the five-year survival, the five-year vital status of cases recorded was verified in the National Registry of Identification and Civil Status (RENIEC in Spanish). A linear regression model was used to assess the correlation between [1 – MIR] and total observed five-year survival for the selected cancers. Results: Observed and estimated five-year survival determined by [1 – MIR] for each neoplasia were thyroid (66.7%, 86.7%), breast (69.6%; 68%), prostate (64.3%, 63.8%) and cervical (50.1%, 58.5%), respectively. Pearson’s r coefficient for the correlation between [MIR – 1] and observed survival was = 0.9839. Using the coefficient of determination, it was found that [1 – MIR] (X) captures the 96.82% of observed survival (Y). Conclusion: The Mortality–Incidence Ratio complement [1 – MIR] is an appropriate tool for approximating observed five-year survival for the ten types of cancers studied. This study demonstrates the validity of this model for predicting five-year survival in cancer patients in metropolitan Lima.
Type:
info:eu-repo/semantics/article
Rights:
info:eu-repo/semantics/openAccess
Language:
eng
Keywords:
Cancer; Cancer registries; Incidence; Mortality; Mortality/incidence ratio; Peru; Survival
ISSN:
17546605

Full metadata record

DC FieldValue Language
dc.contributor.authorStenning-Persivale, Karolinees
dc.contributor.authorSavitzky Franco, Maria Josees
dc.contributor.authorCordero-Morales, Alejandraes
dc.contributor.authorCruzado-Burga, Josées
dc.contributor.authorPoquioma, Ebertes
dc.contributor.authorDíaz Nava, Edgares
dc.contributor.authorPayet, Edouardoes
dc.date.accessioned2018-02-12T14:57:26Z-
dc.date.available2018-02-12T14:57:26Z-
dc.date.issued2018-01-18-
dc.identifier.citationThe mortality-incidence ratio as an indicator of five-year cancer survival in metropolitan Lima 2018, 12 ecancermedicalsciencees
dc.identifier.issn17546605-
dc.identifier.doi10.3332/ecancer.2018.799-
dc.identifier.urihttp://hdl.handle.net/10757/622636-
dc.description.abstractIntroduction: The Mortality–Incidence Ratio complement [1 – MIR] is an indicator validated in various populations to estimate five-year cancer survival, but its validity remains unreported in Peru. This study aims to determine if the MIR correlates directly with five-year survival in patients diagnosed with the ten most common types of cancer in metropolitan Lima. Materials and methods: The Metropolitan Lima Cancer Registry (RCLM in Spanish) for 2004–2005 was used to determine the number of new cases and the number of deaths of the following cancers: breast, stomach, prostate, thyroid, lung, colon, cervical, and liver cancers, as well as non-Hodgkin’s lymphoma and leukaemia. To determine the five-year survival, the five-year vital status of cases recorded was verified in the National Registry of Identification and Civil Status (RENIEC in Spanish). A linear regression model was used to assess the correlation between [1 – MIR] and total observed five-year survival for the selected cancers. Results: Observed and estimated five-year survival determined by [1 – MIR] for each neoplasia were thyroid (66.7%, 86.7%), breast (69.6%; 68%), prostate (64.3%, 63.8%) and cervical (50.1%, 58.5%), respectively. Pearson’s r coefficient for the correlation between [MIR – 1] and observed survival was = 0.9839. Using the coefficient of determination, it was found that [1 – MIR] (X) captures the 96.82% of observed survival (Y). Conclusion: The Mortality–Incidence Ratio complement [1 – MIR] is an appropriate tool for approximating observed five-year survival for the ten types of cancers studied. This study demonstrates the validity of this model for predicting five-year survival in cancer patients in metropolitan Lima.es
dc.formatapplication/pdfes
dc.language.isoenges
dc.publisherCancer Intelligencees
dc.relation.urlhttp://www.ecancer.org/journal/12/full/799-the-mortality-incidence-ratio-as-an-indicator-of-five-year-cancer-survival-in-metropolitan-lima.phpes
dc.rightsinfo:eu-repo/semantics/openAccesses
dc.subjectCanceres
dc.subjectCancer registrieses
dc.subjectIncidencees
dc.subjectMortalityes
dc.subjectMortality/incidence ratioes
dc.subjectPerues
dc.subjectSurvivales
dc.titleThe mortality-incidence ratio as an indicator of five-year cancer survival in metropolitan Limaes
dc.typeinfo:eu-repo/semantics/articlees
dc.identifier.journalecancermedicalsciencees
dc.description.fundingWe would like to thank the Department of Epidemiology and Statistics of the National Cancer Institute (INEN) and the entire departmental staff.es_PE
dc.description.peerreviewRevisión por pareses_PE
All Items in UPC are protected by copyright, with all rights reserved, unless otherwise indicated.